BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
FGF21
,
Angiogenesis
,
Leukemia
,
Kidney
,
Personalized medicine
,
Lipitor
,
rs2300478
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
genes c myc
Summary
General Info
Curated Studies
Most Correlated Studies
Induced pluripotent stem cells by direct delivery of Oct4, Sox2, Klf4,and c-Myc proteins
Mantle cell lymphoma in Cdk4R24C c-myc-3’RR transgenic mice
Mantle cell lymphomas from c-MYC-transgenic mice with CDK4[R24C] or TP53 mutations
Mammary fibrocystic disease MCF10A cells with HER, c-MYC, or HER plus c-MYC double overexpression
Generation of induced pluripotent stem cells from cord blood using OCT4 SOX2 C-MYC and KLF4
Explore Curated Studies Results
Literature
Most Relevant Literature
Amplifiation of the c-MYC gene in acinar prostate adenocarcinoma. Morphogenic comparisons].
Radiosensitizing Effect of Celastrol by Inhibiting G2/M Phase Arrest Induced by the c-myc Gene of Hu…
Plasmablastic lymphomas show restricted EBV latency profile and MYC gene aberrations.
Distinguishing G-Quadruplexes Stabilizer and Chaperone for c-MYC Promoter G-Quadruplexes through Sin…
HIV-associated DLBCL: Clinicopathological factors including dual-colour chromogenic in situ hybridis…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL W…
Gene Abnormalities and Prognosis in Diffuse Large B-cell Lymphoma
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ